Core Viewpoint - The company, China National Pharmaceutical Group Corporation (Sinopharm), reported that its business remains relatively stable, but it anticipates a highly competitive market landscape in the short term [1] Group 1: Business Performance - The company emphasized the importance of balancing accounts receivable and sales revenue while focusing on quality assurance [1] - Future profitability is expected to gradually improve as the company navigates the competitive environment [1]

Core Viewpoint - The company emphasizes its commitment to the pharmaceutical and health products sector, focusing on high-margin proprietary brands and leveraging the brand effect of the China National Pharmaceutical Group [1] Group 1: Company Strategy - The company continues to focus on the health sector, particularly in response to the significant impact of policy adjustments on traditional pharmaceuticals [1] - The company plans to adjust its product offerings by expanding its proprietary products based on patient needs [1] Group 2: Supply Chain and Collaboration - The company aims to enhance its supply chain efficiency through increased collaboration with manufacturers and improved logistics [1] - The company will emphasize related products within the China National Pharmaceutical Group's system to strengthen its market position [1]

Group 1 - The company announced on September 3 that there are differences in distribution business between the Guangxi and Guangdong regions [1] - In the Guangxi market, the company is gradually narrowing the gap with major competitors and is confident in further increasing market share [1] - The competition in Guangdong is more intense, with a larger market size, and the company plans to focus more on operational quality rather than short-term revenue differences [1] Group 2 - The company emphasizes the importance of long-term stable development, ensuring sufficient cash flow and profit support [1]

Core Viewpoint - The company, China National Pharmaceutical Group Corporation (Sinopharm), announced on September 3 that it will continue to enhance its qualifications for obtaining narcotic and psychotropic substances [1] Group 1 - The company will increase its efforts in acquiring qualifications for narcotic and psychotropic substances [1] - The internal collaboration of narcotic and psychotropic product resources and national distribution platforms within the group will be strengthened [1] - The company aims to continuously introduce better product varieties to enhance coverage [1]

Core Viewpoint - The company is gradually improving its cost and expense management through investments in automation and IT systems to enhance work efficiency and reduce labor costs [1] Group 1 - The company announced on September 3 that it is making progress in managing costs and expenses [1] - Investments in automated equipment and IT systems are contributing to increased work efficiency [1] - In the first half of the year, the company achieved certain savings in sales and management expenses, partly due to the application of information systems and digitalization [1]

（编辑 袁冠琳） 证券日报网讯 国药一致9月3日发布公告，在公司回答调研者提问时表示，公司首先保持传统业务的优 势地位，如集采品种。同时加大与厂家，尤其是创新药企的合作。公司在等级医院覆盖方面，专门成立 管理中心以提升公司在创新药产品进入医院的准入能力，能够提供全方位服务，吸引创新药企业与公司 有更多的合作。 ...

（编辑 袁冠琳） 证券日报网讯 国药一致9月3日发布公告，在公司回答调研者提问时表示，国大药房目前强调稳健和提 质增效，短期不太会有并购计划，会把重点放在现有店铺经营能力的提升方面。未来行业进入稳定阶 段，不排除再进行扩张的可能。 ...

Core Viewpoint - The company announced that it conducts annual impairment tests on goodwill in accordance with accounting standards and policies, with results pending further evaluation after the second half of the year [1] Group 1 - The company stated that it reflects the value of goodwill assets accurately based on the results of impairment tests [1] - Current conditions regarding goodwill are relatively stable, with specific results to be assessed later [1]

Core Viewpoint - The company announced that it does not plan to close a large number of stores in the second half of the year, despite the impact of online business on offline operations [1] Group 1: Company Strategy - The company is actively embracing online business while also adjusting its product categories to enhance competitiveness in attracting customer traffic [1] - The company acknowledges that the pharmaceutical business is unique, and online sales will not completely replace offline sales [1]

（编辑 袁冠琳） 证券日报网讯 国药一致9月3日发布公告，在公司回答调研者提问时表示，公司去年年初制定了三年的 分红承诺，即不低于20%派息率，但今年已经做到超过30%。从长远来看，公司会结合现金的实际情况 进行分红，也会在经营条件允许的范围内给投资者合理回报，总体不会低于20%。 ...